1. Home
  2. BMBL vs ABUS Comparison

BMBL vs ABUS Comparison

Compare BMBL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

HOLD

Current Price

$5.94

Market Cap

783.9M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.21

Market Cap

836.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMBL
ABUS
Founded
2014
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
783.9M
836.0M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
BMBL
ABUS
Price
$5.94
$4.21
Analyst Decision
Hold
Analyst Count
12
0
Target Price
★ $4.05
N/A
AVG Volume (30 Days)
★ 10.5M
6.1M
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
N/A
★ 0.84
Revenue
★ $965,658,000.00
$14,083,000.00
Revenue This Year
N/A
$1,208.75
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.99
Revenue Growth
N/A
★ 128.21
52 Week Low
$2.44
$3.50
52 Week High
$5.98
$5.45

Technical Indicators

Market Signals
Indicator
BMBL
ABUS
Relative Strength Index (RSI) 89.17 37.35
Support Level $2.66 $4.17
Resistance Level N/A $4.57
Average True Range (ATR) 0.15 0.18
MACD 0.26 0.00
Stochastic Oscillator 98.87 17.33

Price Performance

Historical Comparison
BMBL
ABUS

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: